Advanced Search

 

Study ID Status Title Patient Level Data
P42-16 Completed A Multicenter, Placebo-Controlled Parallel-Design, Phase III Evaluation of the Safety of Lamotrigine (LAMICTAL) as Add-On Therapy in Outpatients with Partial Seizures
P66/H73-005 Completed An International, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 50 Years of Age or Older
P66/H73-006 Completed A Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients Less Than 50 Years Old
P66/H73-012 Completed Pharmacokinetic Analysis: Oral 256U87 Safety, Pharmacokinetics, and Prophylaxis of Cytomegalovirus Infection and Disease in Renal Allograft Recipients
P66/H73-012 (CMV Seronegative Recipients) Completed Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients
P66/H73-012 (CMV Seropositive Recipients) Completed Oral 256U87 (Valaciclovir) Safety, Pharmacokinetics and Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients
P66-09 (123-009) Completed Single-Dose Pharmacokinetics and Safety of Valaciclovir in Volunteers with End-Stage Renal Disease
P66-10 Completed Pharmacokinetics and Safety of Acyclovir and Valaciclovir Following Single and Multiple Oral Administration of Valaciclovir in Geriatric Volunteers With and Without Concomitant Diuretic Therapy
P66-H73-003 Completed A Comparative Trial of Valacyclovir and Acyclovir for the Treatment of First-Episode Genital Herpes Infection
PAD20001 Completed A multi-center, three-staged with interim analyses, parallel, randomized, double-blind, fenofibrate-and placebo-controlled proof of concept and dose-response evaluation of the safety, tolerability, and effects on plasma high-density lipoprotein cholesterol (HDLc) and triglycerides of eight weeks treatment with GW501516 in otherwise healthy patients with low HDLc, mildly to moderately elevated triglycerides, and normal low-density lipoprotein cholesterol (LDLc)
PAR MDSA/29060/III/86/1182 Completed A Study to Assess the Tolerance of Paroxetine in Short and Long Term Therapy and to Assess the Efficacy and Tolerance in a Subset of Patients in whom Previous Antidepressant Therapy had Failed. An Open Study
PAR03_001 Completed A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients Study Listed on ClinicalStudyDataRequest.com
PC 90-01 Completed Pharmacokinetics and Safety of Lamotrigine in Young Epileptic Children
PCR103124 Completed A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression
PCR104074 Completed A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated Geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects
PCR104075 Completed A steady-state study to assess the pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release paroxetine tablet (25 mg) in healthy Chinese subjects
PCR111656 Completed An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga Study Listed on ClinicalStudyDataRequest.com
PGA105446 Completed Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
PGAA1001 Completed A phase I study of 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-purine (Compound 506) in children and adults with refractory hematologic malignancies.
PGAA1002 Completed A phase I study of 506U78 administered as a two hour infusion daily for 3 consecutive days in adult patients and as a two hour infusion daily over 5 consecutive days in pediatric patients with refractory hematologic malignancies.
PGAA1003 Completed Phase I study of 506U78 administered as a two hour infusion on a day 1, 3, and 5 schedule in patients with refractory hematologic malignancies.
PGAA1005 Completed Pilot study of pharmacodynamic investigation of treatment with 506U78 combined with fludarabine in refractory leukemics.
PGAA2001 Completed A Phase II Study of 506U78 in Patients with Refractory T-Cell Malignancies – CCG Intergroup Study
PGAA2003 Completed A Multicenter Study to Assess the Efficacy of 506U78 in Subjects with Chronic Lymphocytic Leukemia (CLL) who are Refractory to Fludarabine and Alkylator Therapy
PHX111427 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.